## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

) Art Unit:

) Examiner:

To be Assigned

To be Assigned

Application of : BAILEY, M. D. et. al. U.S. Appln. No. : To be Assigned

Title of Invention : Hepatitis C Inhibitor Peptide Analogs

Confirmation No. : To be Assigned U.S. Filing Date :

Attny. Docket No.: 13/128 NS							
P. O. Box 14	er for Patents 50 VA 22313-1450						
TRANSM	MITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT						
Sir:							
	herewith concerning the subject application is an Information Disclosure orm 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described						
∑ 197(b). This Statement is being filed: 1) within three (3) months of the filting date of a national application other than a continued prosecution application under 33 CFR, §15.3 (6); ii) within three (3) months of the date of early of the national stage as set fort in 37 CFR, §1.491 in an international application; iii) before the mailing of a first Office action on the merits, or it) before the mailing of a first Office action after the filting of a request for continued examination under 37 CFR, §1.14.							
notice of allo	c). This Statement is being filed after the time period specified in 37 (b), but before the mailing date of: i) a final action under 37 CFR, §1.113, ii) a wance under 37 CFR, §1.111, or iii) an action that otherwise closes in the application. This Statement is being accompanied by:						
	A statement as specified in 37 C.F.R. §1.97(e) [see below]; or						
	The fee set forth in 37 C.F.R. §1.17(p).						
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.						

1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(e) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 57 C.F.R. §1.97(e) [see below] and the fee set forth in 57 C.F.R. §1.17(p).					
1.97(e).					
☐ Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or					
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a commerpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant of the instant o					
The fee set forth in 37 C.F.R. §1.17(p).					
☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.					
☐ 1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in socion 1.5(e) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.					

 The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patient application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Respectfully submitted,

/Philip I. Datlow/

Philip I. Datlow Attorney for Applicant(s) Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877 Tel: (203) 798-4542

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031 U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

to a collection of information unless if contains a valid OMB control number Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Subabbide for from 14494/0TO

(Use as many sheets as necessar)

Application Number	To be Assigned
Filing Date	
First Named Inventor	BAILEY, Murray D., et. al.
Art Unit	
Examiner Name	

Altomey Docket Number 13/128-NS

U. S. PATENT DOCUMENTS Document Number Applicant of Cited Documen elevant Passages or Relevant Figures Appear Number-Kind Code<sup>2 (Finese</sup> US-6,869,964 B2 04.15.2004 CAMPBELL et al. US-6.323.180 11-27-2001 BAILEY, et al. US- 2005/187165 A1 05-26-2005 SCOLA et al. US- 2005/0020503 A1 01-27-2005 M ITINAS-BRUNET et al. US US-US US-US US-US US-HS

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (Filmown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	l
		CA 2,445,938 A1	02-24-2000	Boehnnger Ingelheim (Ceneda) Ltd			1
		WO 2005/046712 A1	05-26-2005	Bristol-Myers Squibb Com(pany		Г	1
		WO 00/09543	02-24-2000	Boehringer Ingeliveim (Canada) Lld			1
		WO 03/064456 A1	08-07-2003	Ecotringer Ingelterm International GmbH		Г	1
		WO 03/064416 A1	08-07-2003	Buildings Ingolerin International Onti-		г	1

Signature Considered

EXAMINER Initial if reference considered, whether or not distion is in conformance with MPEP 609. Daw line through distion if not in conformance and no considered. Include copy of this form with next communication to applicant. § Applicant's unique citation designation number (optional). § See Kinds Codes of USPTO Patent Documents at www uspto gov or MPEP 901 04. 3 Enler Office that issued the document, by the two-letter code (WIPO Standard ST 3) 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the accropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTC) to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments inducing gardening, preparing, and scontaing the companies appealable from the two way depending upon the induction case. Any continuous on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tasiemark Officer U.S. Decartment of Commerce, P.O. Box 1459. Alexandria Via 22313-1459. DO NOT SEND FEES OR COMPLETIO FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0551-0031 U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ed to a collection of information unless it contains a valid OMB control number Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for from 14494/9TO

(Use as many sheets as necessary

Application Number To be Assigned Filling Date First Named Inventor BAILEY, Murray D., et. al. Art Unit 1614 Examiner Name Altomey Docket Number 13/128 NS

			U. S. PATENT D	OCUMENTS	
caminer ibals*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Oited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code <sup>2</sup> (Finance)		Applicant or College Document	Figures Appear
		US-			
	-	US-			
		US-			

#### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (Filmown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	l
		WO 2004/101602 A2	11-25-2004	Bodenger Ingelberen Intersekonel Centro			1
		WO 2004/101605 A1	11-25-2004	Contanger Ingelteen International Centre		Г	1
		WO 2004/103996 A1	12-02-2004	Horizoger Ingelteen Intersectional Contril			1
	I	WO 02/060926 A2	08-08-2002	Bristol-Myers Squibb Company		Γ.	1
	l	WO 03/053349 A2	07-03-2003	Bristol-Myers Squibb Company		Г	1

Signature Considered

\*EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 609. Draw line through dilation if not in conformance and no considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (potonal). 2 See Kinds Codes of USPTO Patent Documents at www.usoto.com or MPEP 901 04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the accropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or relain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including pathwaying, preparing, and submitting the completed application form to the USPTO. Time will savy depending upon the individual case. Any comments inducing garbeing, preparing, and commissing the commission form to the control of the way depending upon the inductoral case. Any commission on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandra, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0551-0031 U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ed to a collection of information unless it contains a valid OMB control number Complete if Known Subabbide for from 14494/0TO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary

Application Number	To be Assigned				
Filing Date					
First Named Inventor	BAILEY, Murray D., et. al.				
Art Unit					
Examiner Name					
Attorney Docket Number	13/128-NS				

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
nibals*	Cite No.1	DOCUMENT NUMBER	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant
		Number-Kind Code <sup>2 (Finces)</sup>		.,,	Figures Appear
		US-		1	
	П	US-			
		US-			
	-	US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>9</sup> (Filmown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	l
		WO 03/099316 A1	12-04-2003	Bristol-Myers Squibb Company			1
		WO 03/099274 A1	12-04-2003	Bristol-Myers Squibb Company		Г	1
		WO 2004/032827 A2	04-22-2004	Bristol-Myers Squibb Company		Г	1
		WO 2004/043339 A2	05-27-2004	Bristol-Myers Squibb Company			1
	I					$\overline{}$	1

Signature Considered

\*EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 609. Draw line through dilation if not in conformance and no considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (potional). 2 See Kinds Codes of USPTO Patent Documents at www.usoto.com or MPEP 901 04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the accropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or relain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including pathwaying, preparing, and submitting the completed application form to the USPTO. Time will savely depending upon the individual case. Any comments inducing garrianting, preparing, and commissing the commission form to the control of the way depending upon the induction case. Any commission on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandra, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.